

Ramon Rossi Lopez (admitted *pro hac vice*)  
(CA Bar No. 86361)  
LOPEZ McHUGH LLP  
100 Bayview Circle, Suite 5600  
Newport Beach, California 92660  
[rlopez@lopezmchugh.com](mailto:rlopez@lopezmchugh.com)

Mark S. O'Connor (011029)  
GALLAGHER & KENNEDY, P.A.  
2575 East Camelback Road  
Phoenix, Arizona 85016-9225  
Telephone: (602) 530-8000  
[mark.oconnor@gknet.com](mailto:mark.oconnor@gknet.com)

*Attorneys for Plaintiffs*

Richard B. North, Jr. (admitted *pro hac vice*)  
Georgia Bar No. 545599  
Matthew B. Lerner (admitted *pro hac vice*)  
Georgia Bar No. 446986  
NELSON MULLINS RILEY &  
SCARBOROUGH LLP  
201 17th Street, NW / Suite 1700  
Atlanta, GA 30363  
Telephone: (404) 322-6000  
Telephone: (602) 382-6000  
[richard.north@nelsonmullins.com](mailto:richard.north@nelsonmullins.com)  
[matthew.lerner@nelsonmullins.com](mailto:matthew.lerner@nelsonmullins.com)

*Attorneys for Defendants C. R. Bard, Inc. and  
Bard Peripheral Vascular, Inc.*

UNITED STATES DISTRICT COURT

DISTRICT OF ARIZONA

In Re Bard IVC Filters Products  
Liability Litigation

No. MD-15-02641-PHX-DGC

SHERR-UNA BOOKER, an individual,  
  
Plaintiff,

v.

C.R. BARD, INC., a New Jersey  
corporation and BARD PERIPHERAL  
VASCULAR, an Arizona corporation,  
  
Defendants.

**PLAINTIFF'S PROPOSED  
ADDITIONAL VOIR DIRE  
QUESTIONS AND DEFENDANTS'  
OBJECTIONS**

(The Honorable David G. Campbell)

1 Plaintiff Sherr-Una Booker and Defendants C.R. Bard, Inc. and Bard Peripheral  
2 Vascular, through their respective counsel, hereby submit the proposed additional voir dire  
3 questions and Defendants' objections as directed in the Court's Case Management Order  
4 No. 31 [Doc. 10323].

5 **PLAINTIFF'S PROPOSED FDA VOIR DIRE QUESTIONS**

6 1. Is there anyone on the panel who has worked for the United States Food and  
7 Drug Administration ("FDA")?

8 2. Is there anyone here who is unwilling to follow my instruction about the  
9 FDA and the nature and effect of its role in this case?

10 3. Is there anyone who has knowledge of or experience with the process of the  
11 FDA for having a product or device cleared to place on the market?

12 4. Is there anyone who believes that if a medical device corporation submits an  
13 application to the FDA to sell a medical device and the FDA cleared it, that means the  
14 corporation acted reasonably?

15 5. Is there anyone who believes that if a medical device corporation submits its  
16 product to FDA for clearance the device must be safe and effective?

17 6. Does anyone believe that if the FDA does not require a medical device  
18 corporation to recall its product, then the product must not be defective?

19 7. Does anyone believe that a medical device corporation must first obtain  
20 approval from the FDA before warning the public about risks and dangers it knows about  
21 its product?

22 8. Is there anyone who feels that you would be prevented from finding against  
23 the medical device corporation if the FDA cleared the medical device corporation to sell  
24 its medical device to the public?

25 9. Is there anyone who believes that if a medical device corporation submitted  
26 its product to the FDA for clearance that means the device must be safe and effective and  
27 therefore would begin the case with a bias against the plaintiff and in favor of the  
28 defendant?

**THE DEFENDANTS' OBJECTIONS:**

The Defendants do not object to the content of Question Nos. 1 and 3, although they believe the answers to those questions would have already been provided as a part of the Juror Questionnaire (and specifically, in response to Question Nos. 12, 40, 43 and 52, either alone or in combination).

The Defendants object to the remaining questions listed in the Plaintiffs' proposed additional voir dire questions. Those questions are argumentative; they seek to bias the jury; and they seek to commit the jurors to a pre-determined outcome. The issues raised in those questions can be readily addressed via objections to any testimony that the Plaintiffs believe misconstrue the nature of the regulatory process.

RESPECTFULLY SUBMITTED this 7<sup>th</sup> day of March, 2018.

GALLAGHER & KENNEDY, P.A.

SNELL & WILMER L.L.P.

By: /s/ Mark O'Connor

Mark S. O'Connor (011029)  
2575 East Camelback Road  
Phoenix, Arizona 85016-9225

Ramon Rossi Lopez  
(admitted *pro hac vice*)  
CA Bar No. 86361  
LOPEZ McHUGH LLP  
100 Bayview Circle, Suite 5600  
Newport Beach, California 92660  
*Attorneys for Plaintiffs*

By: /s/ Kate Helm

James R. Condo (005867)  
Amanda C. Sheridan (027360)  
One Arizona Center  
400 E. Van Buren, Suite 1900  
Phoenix, Arizona 85004-2202

Richard B. North, Jr. (*pro hac vice*)  
Georgia Bar No. 545599  
Matthew B. Lerner (*pro hac vice*)  
Georgia Bar No. 446986  
Nelson Mullins Riley & Scarborough  
LLP  
201 17th Street, NW / Suite 1700  
Atlanta, GA 30363  
*Attorneys for C. R. Bard, Inc. and  
Bard Peripheral Vascular, Inc.*

**CERTIFICATE OF SERVICE**

I hereby certify that on this 7<sup>th</sup> day of March, 2018, I electronically transmitted the attached document to the Clerk's Office using the CM/ECF System for filing and transmittal of a Notice of Electronic Filing.

Gay Mennuti